For patients with special considerations, Quzyttir may be a preferred option

Grandpa and granddaughter playing guitar together Grandpa and granddaughter playing guitar together
Line drawing of running child representing pediatrics
Pediatrics1*
Safety and efficacy established in patients 6 months to 17 years of age.
Quzyttir is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function.
Adolescents 12 years of age and older: The recommended dosage is 10 mg administered by intravenous injection.
Please see full Prescribing Information for dosing guidance for children younger than 12 years of age.
Line drawinng of senior citizen walking with cane to represent geriatrics
Geriatrics1
No overall differences in safety were observed between patients ≥65 and younger patients.
In clinical trials with Quzyttir, 18 patients were 65 years and older, and 6 patients were 75 years and older. No overall differences in safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Line drawing of heart with heartbeat inside to represent cardiac concerns
Cardiac concerns1†
No clinically significant increase in QTc, including in combination with erythromycin, ketoconazole, and azithromycin.
Line drawing of liver and kidneys to represent impairment in those areas
Renal and hepatic impairment1†
No dosage adjustments in patients with moderate and severe renal impairment and in patients on dialysis.
No dosage adjustment in patients with hepatic impairment.
Quzyttir is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.
  • *Based on an extrapolation of data from the phase 3 pivotal trial with adult patients, pharmacokinetic data, and studies/cases of oral cetirizine use in pediatric patients.
  • †Based on studies with the oral formulation of cetirizine, the active ingredient in Quzyttir.

Leading medical associations recommend use of
2nd-generation antihistamines

Recommendations for older adults

American Geriatrics Society (AGS)

As a drug with strong anticholinergic properties, Beers Criteria® recommends avoiding oral diphenhydramine (DPH) due to risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity.2
Use of DPH for acute treatment of severe allergic reaction may be appropriate.

NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®) Older Adult Oncology

State that commonly used 1st-generation antihistamines, including DPH, are of concern when used in older patients. Negative effects include anticholinergic toxicities, confusion, and cognitive impairment.3
Additional recommendations for general population

American Academy of Emergency Medicine (AAEM)

Recommend 2nd-generation H1 antagonists over 1st-generation H1 antihistamines due to poor central nervous system (CNS) penetration and less sedation.4

American Academy of Allergy, Asthma & Immunology (AAAAI)

1st-generation antihistamines are rapid acting and effective; however, they can be associated with sedation and impaired motor skills.5
For acute urticaria, patients should be made aware of sedation and impaired motor skills associated with 1st-generation antihistamines.5

American Academy of Family Physicians (AAFP)

For urticaria and angioedema, 2nd-generation antihistamines are first-line medications.6
For more information or to request a rep visit, call 1-8‍66-QUZYTTIR